Latigo Biotherapeutics Q3 Net Loss Narrows 16% to $20.95 Million

• Latigo Biotherapeutics’ third-quarter 2026 net loss narrowed 16% year over year to $20.95 million.
• R&D expenses fell 21% to $17.5 million, while general and administrative expenses more than doubled to $5.43 million year over year.
• Cash and cash equivalents totaled $401.2 million at September 30, expected to fund operations into 2029.
• Onzotrigine’s Phase 3 bunionectomy and open-label safety trials remain on track for initiation, with topline results expected in the second half of 2027.
• The ongoing Phase 2 LTG-321 chronic-pain trial is expected to report topline results in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Latigo Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050647PRIMZONEFULLFEED9870856) on November 05, 2026, and is solely responsible for the information contained therein.